New breast cancer drug data a boost for Eli Lilly
Adding its medicine abemaciclib to standard therapy reduces risk of disease progression by 46%; its efficacy is seen as comparable to that of rival drugs from Pfizer, Novartis
New York
ELI Lilly staked its claim for a slice of sales in a new class of breast cancer drugs on Sunday as clinical data showed adding its medicine abemaciclib to standard therapy reduced the risk of disease progression by 46 per cent.
Experts at the European Society for Medical Oncology (ESMO) congress in Madrid said the experimental drug's efficacy was comparable to that of rival drugs from Pfizer and Novartis already on the market.
Abemaciclib, like Pfizer's Ibrance and Novartis's Kisqali, belongs to a class of oral medicines called CDK 4/6 inhibit…
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
Gucci-owner Kering posts 10% drop in Q1 sales on sluggish Chinese demand
China bubble-tea chain Chabaidao plunges on Hong Kong debut
Japan’s 7-Eleven convenience chain targets aggressive global growth
Parental fury after stem cell bank ruins thousands of samples in Singapore
China’s bubble tea boom creates a half-dozen billionaires
US sues to block Coach owner’s US$8.5 billion buyout of Versace parent